Nashville, Tennessee (PRWEB) June 30, 2015
DiaTech Oncology, provider of CorrectChemo®, the drug response profiling test to help oncologists provide personalized cancer treatment, will be available through NextGxDx’s online genetic testing marketplace, GeneSourceTM.
“The CorrectChemo® assay provides the oncologist with valuable insight on how a specific patient’s cancer cells react to the drugs being considered for chemotherapy treatment,” said Robert E. Henry, president and chief executive officer for DiaTech. “The NextGxDx platform enhances our market reach, and we’re pleased to be a part of their platform.”
Adding DiaTech’s CorrectChemo assay to its platform continues NextGxDx’s efforts to broaden the scope of cancer diagnostics in its GeneSource catalog with emerging cell-based assays. CorrectChemo is the only diagnostic test available that delivers, within 72 hours, a ranking of the ability of chemotherapeutic agents to kill tumor cells in an individual patient sample. This patient-specific cancer testing provides oncologists with a unique data set to develop a treatment plan tailored to each patient’s individual chemotherapy needs. Clinically published studies have shown that CorrectChemo utilization resulted in improved survival rates.
DiaTech’s laboratories in Franklin, Tennessee, and Montreal, Canada are CLIA-certified, and were recently accredited through College of American Pathology. In addition, DiaTech is also a Medicare approved lab.
“As a company, we seek to inform our thousands of users about innovative tests in the marketplace, and are especially pleased to add DiaTech Oncology’s CorrectChemo assay,” stated Mark Harris, PhD, MBA and chief executive officer of NextGxDx. “We believe this diagnostic test to be highly complimentary to our catalog of oncology-focused tests.”
About Diatech Oncology
Based in Franklin, Tenn., DiaTech Oncology is a privately held life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine a cancer treatment plan for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. Now called CorrectChemo, the test evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are effective in inducing cancer cell death. It is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. DiaTech has CLIA and CAP certified laboratories in Franklin, Tenn. and Montreal, Canada.
NextGxDx is a healthcare IT company dedicated to improving the genetic test ordering process for the medical community. GeneSourceTM, NextGxDx’s genetic testing database and online marketplace, offers healthcare providers the ability to access up-to-date listings of all genetic tests from CAP, CLIA and Medicare-approved laboratories, view pertinent information about each test, order tests online, and manage results electronically within the HIPAA-compliant portal. As the genetic testing resource, NextGxDx provides comprehensive, intuitive solutions that address the specific challenges faced by each segment of the industry. For more information, visit http://www.NextGxDx.com.
SOURCE NextGxDx Inc.